A putative class action filed in federal court in Newark claims Sanofi US is engaged in unlawful sales practices designed to encourage doctors to prescribe its drugs.

The suit claims Sanofi continues to engage in practices similar to ones that were banned in agreements it signed with federal officials in 2007, 2009 and 2012, when the company was accused of misrepresenting to Medicare and Medicaid the average prices of its drugs.